Probiotec Limited
Probiotec Limited Fundamental Analysis
Probiotec Limited (PBP.AX) shows weak financial fundamentals with a PE ratio of 21.99, profit margin of 5.15%, and ROE of 13.26%. The company generates $0.2B in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 39.0/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze PBP.AX's fundamental strength across five key dimensions:
Efficiency Score
WeakPBP.AX struggles to generate sufficient returns from assets.
Valuation Score
ExcellentPBP.AX trades at attractive valuation levels.
Growth Score
ModeratePBP.AX shows steady but slowing expansion.
Financial Health Score
WeakPBP.AX carries high financial risk with limited liquidity.
Profitability Score
WeakPBP.AX struggles to sustain strong margins.
Key Financial Metrics
Is PBP.AX Expensive or Cheap?
P/E Ratio
PBP.AX trades at 21.99 times earnings. This indicates a fair valuation.
PEG Ratio
When adjusting for growth, PBP.AX's PEG of 0.22 indicates potential undervaluation.
Price to Book
The market values Probiotec Limited at 2.78 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 4.76 times EBITDA. This is generally considered low.
How Well Does PBP.AX Make Money?
Net Profit Margin
For every $100 in sales, Probiotec Limited keeps $5.15 as profit after all expenses.
Operating Margin
Core operations generate 9.69 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $13.26 in profit for every $100 of shareholder equity.
ROA
Probiotec Limited generates $4.68 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Probiotec Limited generates limited operating cash flow of $17.17M, signaling weaker underlying cash strength.
Free Cash Flow
Probiotec Limited produces free cash flow of $7.02M, offering steady but limited capital for shareholder returns and expansion.
FCF Per Share
Each share generates $0.09 in free cash annually.
FCF Yield
PBP.AX converts 2.90% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
21.99
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.22
vs 25 benchmark
P/B Ratio
Price to book value ratio
2.78
vs 25 benchmark
P/S Ratio
Price to sales ratio
1.13
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
1.009
vs 25 benchmark
Current Ratio
Current assets to current liabilities
0.81
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.13
vs 25 benchmark
ROA
Return on assets percentage
0.05
vs 25 benchmark
ROCE
Return on capital employed
0.15
vs 25 benchmark
How PBP.AX Stacks Against Its Sector Peers
| Metric | PBP.AX Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 21.99 | 28.54 | Better (Cheaper) |
| ROE | 13.26% | 738.00% | Weak |
| Net Margin | 5.15% | -43982.00% (disorted) | Weak |
| Debt/Equity | 1.01 | 0.34 | Weak (High Leverage) |
| Current Ratio | 0.81 | 2806.01 | Weak Liquidity |
| ROA | 4.68% | -14624.00% (disorted) | Weak |
PBP.AX outperforms its industry in 1 out of 6 key metrics, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Probiotec Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Defensive, Growth, Innovation
EPS CAGR
N/A
Industry Style: Defensive, Growth, Innovation
FCF CAGR
N/A
Industry Style: Defensive, Growth, Innovation